ActivEdge Platform
AI/AR/ML platform powering surgical innovation and intelligent visualization
Company profile
Intraoperative Intelligence Brings Infinite Possibilities
Company profile
Activ Surgical is a surgical intelligence company that has developed the only commercially available dye-free perfusion imaging technology for the operating room. Using patented laser speckle contrast imaging (LSCI), Activ reveals blood flow, tissue perfusion, and critical structures directly from tissue in real time, without requiring injected dyes like ICG fluorescence. The technology is physics-based, quantitative, and repeatable, providing surgeons with continuous perfusion assessment throughout procedures rather than time-limited snapshots. The company's ActivSight Intelligent Light system is FDA-cleared and CE-marked, and has been used in over 2,000 surgical cases across 17+ countries. Activ's technology integrates into multiple surgical platforms including robotic surgery systems, laparoscopic equipment, microscopy/exoscopy platforms, and open surgery settings. The company serves both surgeons directly and partners with surgical platform manufacturers and OEMs to integrate intelligence capabilities into their systems. Activ Surgical's approach addresses a critical limitation in surgery: surgeons make life-critical decisions based on what they can see, but blood flow and tissue viability beneath the surface remain invisible until complications occur. By providing continuous, on-demand perfusion intelligence, the technology enables surgeons to adjust surgical plans in real time—occurring in approximately 20% of cases where the technology is used. Clinical evidence demonstrates significant outcomes including reduced anastomotic leak rates in colorectal surgery and decreased unnecessary tissue removal.
Company description Activ Surgical official website
Mission. Our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety.
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Embedded deployment with recorded integration context.
Recorded integration context: Compatible with existing laparoscopic systems, Compatible with existing robotic surgical systems.
Company milestones
CE Mark approval December 2022, first international procedure completed, over 200 patient procedures, FDA 510(k) clearance in 2021, multiple pilot hospital sites established
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
AI/AR/ML platform powering surgical innovation and intelligent visualization
First modular multimodal advanced visualization system for minimally invasive surgery
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Science advances · Jul 3, 2026
Dye-less quantification of tissue perfusion by laser speckle contrast imaging is equivalent to quantified indocyanine green in a porcine model.Surgical endoscopy · Oct 1, 2024
Clinical Utility of Laser Speckle Contrast Imaging and Real-Time Quantification of Bowel Perfusion in Minimally Invasive Left-Sided Colorectal Resections.Diseases of the colon and rectum · Jun 1, 2024
Real-time near infrared artificial intelligence using scalable non-expert crowdsourcing in colorectal surgery.NPJ digital medicine · Apr 22, 2024
Real-time First-In-Human Comparison of Laser Speckle Contrast Imaging and ICG in Minimally Invasive Colorectal & Bariatric Surgery.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · Dec 1, 2023
Dye-Less Perfusion Quantification of Porcine Gastric Conduit with Laser Speckle Contrast Imaging and Laser Doppler Imaging.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · Sep 1, 2023
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
$30,000+ cost per leak, 12 days additional length of stay
$66,000 per leak, 15 days additional length of stay
12-25% readmission rate, 7-73 days additional length of stay
26% of all medical errors are preventable surgical errors
Preventable medical errors are 3rd leading cause of death
Advanced visualization during surgery to reduce surgical complications
Seamless integration enabling advanced visualization capabilities
Pilot implementation of ActivSight for clinical validation
Over 200 patients treated successfully across multiple IRB studies
Enhanced surgical vision to reduce unintended medical errors
Improved surgical outcomes through enhanced visualization
Real-time blood supply visualization for surgical decision-making
Reproducible real-time blood supply assessment enabling reliable surgical decisions
Integration of laparoscopic perfusion technology for surgical procedures
Anastomotic leak prevention in colorectal surgery using continuous perfusion assessment
2.5% leak rate vs. 5-15% traditional rate; 17.5% of cases resulted in surgical plan adjustments with 0% leaks in that cohort; 11.7% decreased tissue removal by 3.6 cm
05 · Leadership
Leadership profiles and professional links from the current Company record.
06 · Company updates
Recent articles published on Activ Surgical's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies developing surgical technologies enhanced by AI, including robotic surgical systems, AI-powered surgical assistance and navigation tools, autonomous surgical robotics, and surgical data and analytics platforms. Covers both the performance of surgery and the analysis of surgical outcomes and OR efficiency.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.